[artículo] 
inJournal of Clinical Psychopharmacology > Año 2008 - Vol. 28 - No. 2 (Abril) . - pp. 195-202.

Título :	Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder
Tipo de documento:	texto impreso
Autores:	Elias Eriksson, Autor ; Agneta Ekman, Autor ; Suzanne Sinclair, Autor
Fecha de publicación:	2023
Artículo en la página:	pp. 195-202.
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Citalopram, Relación Dosis-Respuesta, Libido, Náuseas, Síndrome Premenstrual - terapia farmacológica.
Resumen:	This is the first placebo-controlled trial evaluating the efficacy of the selective serotonin reuptake inhibitor (SSRI), escitalopram, in the treatment of premenstrual dysphoric disorder (PMDD). Women with PMDD (intention-to-treat population, n = 151) were treated intermittently for 3 months, during luteal phases only, with 10 mg/d escitalopram, 20 mg/d escitalopram, or placebo.
Link:	./index.php?lvl=notice_display&id=30863

[artículo] Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder [texto impreso] / Elias Eriksson, Autor ; Agneta Ekman, Autor ; Suzanne Sinclair, Autor . - 2023 . - pp. 195-202.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2008 - Vol. 28 - No. 2 (Abril) . - pp. 195-202.

Palabras clave:	Citalopram, Relación Dosis-Respuesta, Libido, Náuseas, Síndrome Premenstrual - terapia farmacológica.
Resumen:	This is the first placebo-controlled trial evaluating the efficacy of the selective serotonin reuptake inhibitor (SSRI), escitalopram, in the treatment of premenstrual dysphoric disorder (PMDD). Women with PMDD (intention-to-treat population, n = 151) were treated intermittently for 3 months, during luteal phases only, with 10 mg/d escitalopram, 20 mg/d escitalopram, or placebo.
Link:	./index.php?lvl=notice_display&id=30863